 | Patrick W J C SerruysShow email addressDepartment of Cardiology, National University of Ireland Galway. | National Heart and Lung Institute, Imperial College London. | Imperial College of Science, Technology and ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Patrick W J C Serruys:Expert Impact
Concepts for whichPatrick W J C Serruyshas direct influence:Coronary artery,Myocardial infarction,Balloon angioplasty,Eluting stents,Artery disease,Coronary angiography,Percutaneous coronary,Coronary angioplasty.
Patrick W J C Serruys:KOL impact
Concepts related to the work of other authors for whichfor which Patrick W J C Serruys has influence:Coronary artery,Aortic valve,Myocardial infarction,Eluting stents,Stent thrombosis,Intravascular ultrasound,Balloon angioplasty.
KOL Resume for Patrick W J C Serruys
| Year | |
|---|---|
| 2022 | Department of Cardiology, National University of Ireland Galway. National Heart and Lung Institute, Imperial College London. |
| 2021 | Imperial College of Science, Technology and Medicine, London, UK Department of Cardiology, National University of Ireland, Galway H91 TK33, Ireland. Electronic address: CÚRAM-SFI Centre for Research in Medical Devices, Galway, Ireland. The Lambe Institute for Translational Medicine and Curam, Saolta University Healthcare Group, Galway, Ireland |
| 2020 | Department of Cardiology, Royal Brompton and Harefield Hospitals, Imperial College London, London, UK International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom National University of Ireland Galway, Galway, Ireland |
| Concept | World rank |
|---|---|
| taxus cardiac | #1 |
| kristel wittebols | #1 |
| reveal ifr | #1 |
| oct years | #1 |
| plaque stent | #1 |
| multivessel pci mvpci | #1 |
| invasive functional | #1 |
| absorb mirage | #1 |
| presence uncovered struts | #1 |
| syntax trial patients | #1 |
| late lumen | #1 |
| bioresorption process | #1 |
| vessel size | #1 |
| hd severe ckd | #1 |
| incidence geographical | #1 |
| meres1 trial | #1 |
| absorb clinical investigation | #1 |
| dilatation brs | #1 |
| n1225 | #1 |
| analysis coronary | #1 |
| years clinical outcomes | #1 |
| artery | #1 |
| eluting coronary | #1 |
| revascularization bms | #1 |
| patients mvlmd | #1 |
| implants aged | #1 |
| clinical evaluation treatment | #1 |
| mirage iqr | #1 |
| lower cabg | #1 |
| diameter mld | #1 |
| pes treatment | #1 |
| 778 lesions | #1 |
| twilight patients | #1 |
| xience abbott vascular | #1 |
| ees absorb | #1 |
| interventional absorbable | #1 |
| mvlmd | #1 |
| oct coronary cta | #1 |
| reviparin coronary angioplasty | #1 |
| post procedure | #1 |
| score sxscore | #1 |
| procedure 6 months | #1 |
| treated balloon | #1 |
| frequency lbbb | #1 |
| mortality cabg | #1 |
| strut voids histology | #1 |
| segments adjacent | #1 |
| ≥75years | #1 |
| cordis corporation | #1 |
| histology implantation | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Patrick W J C Serruys
BACKGROUND: We report the 5-year results of the SYNTAX trial, which compared coronary artery bypass graft surgery (CABG) with percutaneous coronary intervention (PCI) for the treatment of patients with left main coronary disease or three-vessel disease, to confirm findings at 1 and 3 years.
METHODS: The randomised, clinical SYNTAX trial with nested registries took place in 85 centres in the USA and Europe. A cardiac surgeon and interventional cardiologist at each centre assessed ...
| Known for Coronary Disease | Pci Cabg | Syntax Trial | Bypass Graft | Patients Macce |
BACKGROUND: Everolimus-eluting stent (EES) reduces the risk of restenosis in elective percutaneous coronary intervention. However, the use of drug-eluting stent in patients with ST-segment elevation myocardial infarction (STEMI) is still controversial. Data regarding the performance of second-generation EES in this setting are scarce. We report the 1-year result of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) trial, comparing EES with ...
| Known for 1 Year | Ees Bms | Myocardial Infarction | Patients Stemi | Cardiac Death |
BACKGROUND: Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for treatment for coronary artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled trial we aimed to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent. Here we report secondary clinical and procedural outcomes after 1 year of follow-up.
METHODS: In a single-blind, multicentre, randomised trial, ...
| Known for Eluting Stent | Metallic Everolimus | Bioresorbable Scaffold | Abbott Vascular | Santa Clara |
BACKGROUND: The anatomical SYNTAX score is advocated in European and US guidelines as an instrument to help clinicians decide the optimum revascularisation method in patients with complex coronary artery disease. The absence of an individualised approach and of clinical variables to guide decision making between coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) are limitations of the SYNTAX score. SYNTAX score II aimed to overcome these ...
| Known for Syntax Score | Patients Cabg | Coronary Artery | 4year Mortality | Bypass Surgery |
OBJECTIVES: The aim of this study was to investigate the impact of reference vessel diameter (RVD) and lesion length (LL) on the relative safety and efficacy of everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES).
BACKGROUND: Lesion length and RVD are well-known predictors of adverse events after percutaneous coronary intervention.
METHODS: Patient-level data were pooled from the randomized SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent ...
| Known for Everolimus Eluting | Coronary Stent | Lesion Length | Ees Pes | Small Vessels |
Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease
[ PUBLICATION ]
BACKGROUND: Excimer laser coronary angioplasty is reported to give excellent procedural results for treatment of complex coronary lesions, but this method has not been compared with balloon angioplasty in a randomised trial.
METHODS: Patients (n = 308) with stable angina and coronary lesions longer than 10 mm on visual assessment were included. 151 patients (158 lesions) were assigned randomly to laser angioplasty and 157 (167 lesions) to balloon angioplasty. The primary clinical ...
| Known for Balloon Angioplasty | Randomised Trial | Excimer Laser | Coronary Artery | Myocardial Infarction |
BACKGROUND: We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.
METHODS: GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries. Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly ...
| Known for 12 Months | Aspirin Monotherapy | Acute Coronary Syndromes | 2 Years | Primary Endpoint |
BACKGROUND: No medium-term data are available on the random comparison between everolimus-eluting bioresorbable vascular scaffolds and everolimus-eluting metallic stents. The study aims to demonstrate two mechanistic properties of the bioresorbable scaffold: increase in luminal dimensions as a result of recovered vasomotion of the scaffolded vessel.
METHODS: The ABSORB II trial is a prospective, randomised, active-controlled, single-blind, parallel two-group, multicentre clinical trial. ...
| Known for Bioresorbable Scaffold | Metallic Stent | Abbott Vascular | Absorb Xience | 3 Year |
OBJECTIVES: This study sought to compare the clinical outcomes of everolimus-eluting stents (EES) versus paclitaxel-eluting stents (PES) in patients with acute coronary syndromes (ACS) and stable coronary artery disease (CAD).
BACKGROUND: Although randomized trials have shown superiority of EES to PES, the safety and efficacy of EES in ACS is unknown.
METHODS: We performed a patient-level pooled analysis from the prospective, randomized SPIRIT (Clinical Evaluation of the XIENCE V ...
| Known for Everolimus Eluting | Coronary Stent | Patients Acs | Ees Pes | Spirit Iii |
OBJECTIVES: This study sought to evaluate the impact of SYNTAX score (SXscore), and compare its performance in isolation and combination with the PAMI (The Primary Angioplasty in Myocardial Infarction Study) score, for the prediction of 1-year clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.
BACKGROUND: Patients with STEMI were excluded from the original SYNTAX score (SXscore) algorithm. ...
| Known for Myocardial Infarction | Eluting Stent | Syntax Score | Year Clinical | Patients Stemi |
OBJECTIVES: This study sought to report the final 5 years follow-up of the landmark LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) trial.
BACKGROUND: The LEADERS trial is the first randomized study to evaluate biodegradable polymer-based drug-eluting stents (DES) against durable polymer DES.
METHODS: The LEADERS trial was a 10-center, assessor-blind, noninferiority, "all-comers" trial (N = 1,707). All patients were centrally randomized to treatment with either ...
| Known for Durable Polymer | Stent Thrombosis | Primary Endpoint | Noninferiority Trial | Coronary Artery |
OBJECTIVES: This study sought to validate the Logistic Clinical SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score in patients with non-ST-segment elevation acute coronary syndromes (ACS), in order to further legitimize its clinical application.
BACKGROUND: The Logistic Clinical SYNTAX score allows for an individualized prediction of 1-year mortality in patients undergoing contemporary percutaneous coronary intervention. It is composed of a ...
| Known for Clinical Syntax | Coronary Intervention | Cardiac Surgery | Year Mortality | Undergoing Percutaneous |
OBJECTIVES: This study sought to demonstrate the 5-year clinical and functional multislice computed tomography angiographic results after implantation of the fully resorbable everolimus-eluting scaffold (Absorb BVS, Abbott Vascular, Santa Clara, California).
BACKGROUND: Multimodality imaging of the first-in-humans trial using a ABSORB BVS scaffold demonstrated at 2 years the bioresorption of the device while preventing restenosis. However, the long-term safety and efficacy of this ...
| Known for Coronary Artery | Absorb Cohort | Eluting Scaffold | Computed Tomography | 5 Years |
OBJECTIVES: The purpose of this study was to compare the 1-year outcome between bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic stent (EES) in ST-segment elevation myocardial infarction (STEMI) patients.
BACKGROUND: The Absorb BVS (Abbott Vascular, Santa Clara, California) is a polymeric scaffold approved for treatment of stable coronary lesions. Limited and not randomized data are available on its use in ST-segment elevation myocardial infarction (STEMI) ...
| Known for Myocardial Infarction | Coronary Stents | Bioresorbable Vascular Scaffold | Everolimus Eluting | Segment Elevation |
Gender and the Extent of Coronary Atherosclerosis, Plaque Composition, and Clinical Outcomes in Acute Coronary Syndromes
[ PUBLICATION ]
OBJECTIVES: This study sought to assess the extent and composition of atherosclerosis contributing to acute coronary syndrome events in women compared with men.
BACKGROUND: Pathological studies suggest that plaque composition and burden may differ by sex. It is unclear whether sex impacts the extent, characteristics, and potential vulnerability of coronary plaques.
METHODS: A total of 697 patients (24% women) with acute coronary syndromes were enrolled in the prospective, multicenter ...
| Known for Plaque Composition | Acute Coronary Syndromes | Coronary Atherosclerosis | Nonculprit Lesions | Unstable Angioplasty |
